306 related articles for article (PubMed ID: 38434706)
1. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.
Zou F; Cui Z; Lou S; Ou Y; Zhu C; Shu C; Chen J; Zhao R; Wu Z; Wang L; Chen Z; Chen H; Lan Y
Front Pharmacol; 2024; 15():1338902. PubMed ID: 38434706
[No Abstract] [Full Text] [Related]
2. A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
Cui Z; Cheng F; Wang L; Zou F; Pan R; Tian Y; Zhang X; She J; Zhang Y; Yang X
Front Pharmacol; 2023; 14():1259908. PubMed ID: 37954852
[No Abstract] [Full Text] [Related]
3. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
Liu W; Du Q; Guo Z; Ye X; Liu J
Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
[No Abstract] [Full Text] [Related]
4. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
[TBL] [Abstract][Full Text] [Related]
5. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
6. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system.
Zhu Z; Liu M; Zhang H; Zheng H; Li J
Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38743462
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Inclisiran in the US FDA Adverse Event Reporting System (FAERS): a focus on overall patient population and sex-specific subgroups.
He Y; Guan X; Zhang Y; Zhu Z; Zhang Y; Feng Y; Li X
Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38676389
[TBL] [Abstract][Full Text] [Related]
8. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
Pan Y; Wang Y; Zheng Y; Chen J; Li J
Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
[TBL] [Abstract][Full Text] [Related]
9. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
[TBL] [Abstract][Full Text] [Related]
10. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
11. A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System.
Shu Y; He X; Liu Y; Wu P; Zhang Q
Clin Epidemiol; 2022; 14():789-802. PubMed ID: 35789689
[TBL] [Abstract][Full Text] [Related]
12. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database.
Jiang Y; Cheng Y; Du Z; Shen Y; Zhou Q; Ji Y; Zhu H
J Psychopharmacol; 2024 Jun; 38(6):567-578. PubMed ID: 38678377
[TBL] [Abstract][Full Text] [Related]
13. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
Li Z; Guo C; Liu X; Qiu Z; Zhang R
Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
[No Abstract] [Full Text] [Related]
14. Safety evaluation of ceftazidime/avibactam based on FAERS database.
Zhang X; Jiang Y; Guo Y; Zhou W; Qiao W; Zhu H; Qi Z
Infection; 2024 Jun; ():. PubMed ID: 38842750
[TBL] [Abstract][Full Text] [Related]
15. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
[TBL] [Abstract][Full Text] [Related]
16. A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system.
Liu M; Gu L; Zhang Y; Zhou H; Wang Y; Xu ZX
Front Pharmacol; 2024; 15():1290975. PubMed ID: 38357304
[No Abstract] [Full Text] [Related]
17. Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023.
Xiong S; Gou R; Liang X; Wu H; Qin S; Li B; Luo C; Chen J
Diabetes Ther; 2024 May; ():. PubMed ID: 38776037
[TBL] [Abstract][Full Text] [Related]
18. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
Zhao D; Long X; Zhou J; Wang J
Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
[TBL] [Abstract][Full Text] [Related]
19. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
20. A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab.
Yun X; Zhou Y; Wu D; Liu Y; Wu Q
Expert Opin Drug Saf; 2024 May; 23(5):581-591. PubMed ID: 38600747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]